JellyFil Ingredients: the Nine Plants on the Printed Panel

The first name printed inside the blend, which under the labelling rule means it is the heaviest of the nine. An Amazonian bark with centuries of traditional use behind it and a short modern record in front of it.

The published work is an analysis of what is in the bark, cell work in rat penile tissue testing a four-plant combination, and one three-month pilot in men, single-arm, with no placebo group and three other ingredients alongside it. None of that is a dose-controlled trial of muira puama in a person.

It is named in this website's own headline because it sits first on the label. That is a statement about the bottle, not about the evidence.

The plant in this bottle with the largest human record, and the one whose trials are easiest to set against a gummy.

A twelve-week randomised trial gave men aged 21 to 56 either 1,500 mg or 3,000 mg a day. Self-rated sexual desire rose from week eight, and serum testosterone and oestradiol did not move at either dose. The authors were explicit that the effect was independent of mood and of hormones, which makes it a desire finding rather than a hormonal one.

A dose-finding study in people whose sexual difficulty came from an antidepressant found 3.0 g a day moved the questionnaires while 1.5 g a day did not, which is the clearest dose-response signal in this reference list. A 175-person safety trial used 3 g a day for twelve weeks and reported improvements in mood, energy and health status. The systematic review calls the overall evidence limited, and it is right to.

Three grams. This bottle's entire blend is 82 mg.

A Brazilian bark, and the plant here with the least to show in people.

The work that exists is antioxidant, anticholinesterase and antifatigue testing in animals. The review of native Brazilian plants used for male sexual difficulty places catuaba and muira puama in the same position: traditional use, animal models, and a proposed mechanism nobody has confirmed in a human trial.

There is a second complication worth knowing. Catuaba is a common name rather than a species, and material sold under it can be Trichilia catigua or Erythroxylum vaccinifolium depending on the supplier. The panel does not say which, and no page here pretends to know.

The first of the three plants the advertising leaves out, and the one that most deserved a mention.

The US Pharmacopeia review of green tea extract and the liver is the reason USP now recommends a cautionary labelling statement on products that carry it. A national survey published in 2024 put green tea among six botanicals that an estimated 15.6 million US adults had taken in the previous thirty days. The LiverTox monograph keeps the running case record and is free to read.

Trials of the active catechin run at around 800 mg of EGCG a day, which is an order of magnitude beyond anything a 82 mg nine-plant blend can hold. So the reason to know this is in the bottle is not the dose. It is that a reader with liver trouble, or taking something already hard on the liver, should be able to see it on the label before buying. The NCCIH page is a good plain-language starting point.

The second omission from the advertising, and the only input anywhere in this blend with its own number beside it.

Five milligrams is roughly a twentieth of a small cup of coffee. The sports-nutrition position stand puts the range that produces a measurable effect at 3 to 6 mg per kilogram of bodyweight, which for a 180-pound man is 245 to 490 mg. The dose-response meta-analysis on blood pressure finds the diastolic effect appearing above about 400 mg a day.

Both directions matter here. It will not keep you awake, and it is not lifting anything either. What it does is make the label honest, and a stimulant with a stated amount belongs on the front of a product page rather than nowhere. MedlinePlus has the consumer summary if you are already counting.

An adaptogen carrying both a hormone signal and a liver signal, which is an unusual pairing and is best stated in one breath rather than in two sections.

The crossover trial in overweight men aged 40 to 70 used a standardised extract delivering 21 mg of withanolide glycosides a day for eight weeks. Testosterone rose 14.7% more than placebo and DHEA-S rose 18% more. Fatigue, vigour, sexual well-being, cortisol and oestradiol showed no significant difference between the groups, which is the part usually left out when that trial is quoted. The male-fertility meta-analysis and the 2026 hormonal meta-analysis cover the wider picture.

The liver signal is documented in case series from Iceland and the US Drug-Induced Liver Injury Network and from India, with the LiverTox monograph maintaining the record. It is uncommon and it is real, and nobody has measured what a fraction of an 82 mg blend contributes to it.

The amino acid the seller's copy leans on hardest, because the body converts it into nitric oxide and nitric oxide is what relaxes a vessel wall.

The trial usually meant is five grams a day for six weeks in fifty men with confirmed organic erectile difficulty. Nine of twenty-nine on arginine reported subjective improvement against two of seventeen on placebo. Every one of those nine had started with low nitric oxide excretion, and the objectively measured blood flow did not change in either group. That is a narrow, honest result and it is worth more than the sentence usually built on it.

Oral arginine is also the inefficient route into the circulation. The meta-analysis of the trials, as corrected pools doses from 1.5 g to 5 g a day, and the review of arginine alongside prescription treatment covers what happens when it is added to a drug that works.

A share of an 82 mg blend is three orders of magnitude away from the trial doses. That is the honest arithmetic and this desk would rather print it than a mechanism story.

Named in the advertising, and the plant the published record treats most sceptically of the nine.

The meta-analysis of eight randomised trials found questionnaire scores beat placebo on both the short and the full index, while total testosterone showed no difference between groups at all. The six-week trial in trained men used 770 mg a day and found the same pattern on the hormone side.

It is also the plant the PDE5 bench assay screened alongside three others and found completely inactive, while the plant printed directly after it on this panel was the one that worked. The seller's line about tribulus stimulating luteinising hormone and therefore testosterone is not what the trials found, and this website does not repeat it.

The third omission, and by some distance the most interesting name on this bottle.

When four plants traditionally used for impotence were screened against human PDE5A1, only Epimedium brevicornum and its active principle icariin were active. PDE5 is the enzyme prescription treatments block. Later work took icariin into cells and into rats, and a structure-activity study traced the activity to specific isolated flavonoids rather than to the raw extract.

Three caveats, all of them load-bearing. A test tube is not a man. An isolated compound is not an extract in a gummy. And nobody has related any of those concentrations to a share of 82 mg.

What survives all three is the practical point: this is the reason anyone taking a nitrate, a blood-pressure medicine or an erectile-dysfunction prescription should raise this bottle with a clinician before starting it rather than after.